Secondary analysis
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute Myocardial Infarction (MI)
- Exploratory analysis of the AEGIS-II randomised trial
- international
- multicentre
- double-blind
- placebo-controlled
Authors' conclusion
Although CSL112 did not significantly reduce the occurrence of the primary study endpoints, patients treated with CSL112 infusions had numerically lower rates of CV death and MI, type-1 MI, and stent thrombosis-related MI compared with placebo.
Study context
- Population
- High-risk patients with acute MI
- Participants
- 18,219 patients
- Comparison
- CSL112 vs placebo
- Primary endpoint
- Cardiovascular (CV) death and recurrent MI
Primary result
As reported in the abstract
CV death and type 1 MI
CSL112 vs PlaceboHazard ratio (95% CI)P value
day 90
0.84(0.7–1.0)
P = 0.056day 180
0.86(0.74–0.99)
P = 0.048day 365
0.89(0.79–1.01)
P = 0.07Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| CV death or any MI — CSL112 vs Placebo · day 90 | 0.92 (0.80–1.05) | |
| CV death or any MI — CSL112 vs Placebo · day 180 | 0.89 (0.79–0.996) | |
| CV death or any MI — CSL112 vs Placebo · day 365 | 0.91 (0.83–1.01) | |
| 0.512Hazard ratio (log scale) |
MI by type
- Effect on MI predominantly observed for type 1 MI and type 4b (stent thrombosis)
Original publication
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI. J Am Coll Cardiol. Published 6 April 2024. doi:10.1016/j.jacc.2024.03.396
Summarised from the published abstract; every number is checked against it